Cargando…

Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India

Isoniazid is the most commonly used drug for treatment of tuberculosis, and is administered individually or in combination with other drugs as standard first line therapy. Offsetting its efficacy, severe adverse effects, especially peripheral neuropathy and hepatotoxicity, are associated with isonia...

Descripción completa

Detalles Bibliográficos
Autores principales: Imam, Faisal, Sharma, Manju, Khayyam, Khalid Umer, Khan, Mohammad Rashid, Ali, Mohammad Daud, Qamar, Wajhul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292862/
https://www.ncbi.nlm.nih.gov/pubmed/32550793
http://dx.doi.org/10.1016/j.jsps.2020.04.003
_version_ 1783546181022908416
author Imam, Faisal
Sharma, Manju
Khayyam, Khalid Umer
Khan, Mohammad Rashid
Ali, Mohammad Daud
Qamar, Wajhul
author_facet Imam, Faisal
Sharma, Manju
Khayyam, Khalid Umer
Khan, Mohammad Rashid
Ali, Mohammad Daud
Qamar, Wajhul
author_sort Imam, Faisal
collection PubMed
description Isoniazid is the most commonly used drug for treatment of tuberculosis, and is administered individually or in combination with other drugs as standard first line therapy. Offsetting its efficacy, severe adverse effects, especially peripheral neuropathy and hepatotoxicity, are associated with isoniazid therapy, limiting its use in tuberculosis. Isoniazid is acetylated in vivo producing hydrazine and acetyl hydrazine, which are responsible for hepatotoxicity. Marked pharmacogenetic differences in acetylation have been reported among different population across the globe. This study evaluates isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National Tuberculosis Control Program (RNTCP) in a specialized tuberculosis hospital in north India. Of 351 patients from whom samples were taken for biochemical analysis of adverse events, 36 were assessed for acetylation patterns. Blood samples were taken 1 h after administration of a 600 mg dose of isoniazid, and plasma concentrations of isoniazid were determined using a validated HPLC method. Of these 36 patients, 20 (55.56%) were slow acetylators and 16 (44.44%) were fast acetylators. Our results are consistent with those of an earlier study conducted in a different region of India. Most biochemical changes produced during long-term isoniazid therapy resolve after therapy is terminated.
format Online
Article
Text
id pubmed-7292862
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-72928622020-06-17 Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India Imam, Faisal Sharma, Manju Khayyam, Khalid Umer Khan, Mohammad Rashid Ali, Mohammad Daud Qamar, Wajhul Saudi Pharm J Article Isoniazid is the most commonly used drug for treatment of tuberculosis, and is administered individually or in combination with other drugs as standard first line therapy. Offsetting its efficacy, severe adverse effects, especially peripheral neuropathy and hepatotoxicity, are associated with isoniazid therapy, limiting its use in tuberculosis. Isoniazid is acetylated in vivo producing hydrazine and acetyl hydrazine, which are responsible for hepatotoxicity. Marked pharmacogenetic differences in acetylation have been reported among different population across the globe. This study evaluates isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National Tuberculosis Control Program (RNTCP) in a specialized tuberculosis hospital in north India. Of 351 patients from whom samples were taken for biochemical analysis of adverse events, 36 were assessed for acetylation patterns. Blood samples were taken 1 h after administration of a 600 mg dose of isoniazid, and plasma concentrations of isoniazid were determined using a validated HPLC method. Of these 36 patients, 20 (55.56%) were slow acetylators and 16 (44.44%) were fast acetylators. Our results are consistent with those of an earlier study conducted in a different region of India. Most biochemical changes produced during long-term isoniazid therapy resolve after therapy is terminated. Elsevier 2020-06 2020-04-19 /pmc/articles/PMC7292862/ /pubmed/32550793 http://dx.doi.org/10.1016/j.jsps.2020.04.003 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Article
Imam, Faisal
Sharma, Manju
Khayyam, Khalid Umer
Khan, Mohammad Rashid
Ali, Mohammad Daud
Qamar, Wajhul
Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India
title Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India
title_full Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India
title_fullStr Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India
title_full_unstemmed Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India
title_short Determination of isoniazid acetylation patterns in tuberculosis patients receiving DOT therapy under the Revised National tuberculosis Control Program (RNTCP) in India
title_sort determination of isoniazid acetylation patterns in tuberculosis patients receiving dot therapy under the revised national tuberculosis control program (rntcp) in india
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7292862/
https://www.ncbi.nlm.nih.gov/pubmed/32550793
http://dx.doi.org/10.1016/j.jsps.2020.04.003
work_keys_str_mv AT imamfaisal determinationofisoniazidacetylationpatternsintuberculosispatientsreceivingdottherapyundertherevisednationaltuberculosiscontrolprogramrntcpinindia
AT sharmamanju determinationofisoniazidacetylationpatternsintuberculosispatientsreceivingdottherapyundertherevisednationaltuberculosiscontrolprogramrntcpinindia
AT khayyamkhalidumer determinationofisoniazidacetylationpatternsintuberculosispatientsreceivingdottherapyundertherevisednationaltuberculosiscontrolprogramrntcpinindia
AT khanmohammadrashid determinationofisoniazidacetylationpatternsintuberculosispatientsreceivingdottherapyundertherevisednationaltuberculosiscontrolprogramrntcpinindia
AT alimohammaddaud determinationofisoniazidacetylationpatternsintuberculosispatientsreceivingdottherapyundertherevisednationaltuberculosiscontrolprogramrntcpinindia
AT qamarwajhul determinationofisoniazidacetylationpatternsintuberculosispatientsreceivingdottherapyundertherevisednationaltuberculosiscontrolprogramrntcpinindia